nystatin-a1 and Trypanosomiasis--African

nystatin-a1 has been researched along with Trypanosomiasis--African* in 1 studies

Other Studies

1 other study(ies) available for nystatin-a1 and Trypanosomiasis--African

Article	Year
Synthesis of 3-azabicyclo[3.2.2]nonanes and their antiprotozoal activities. Bioorganic & medicinal chemistry letters, 2015, Apr-01, Volume: 25, Issue:7 Several bicyclic compounds, 3-azabicyclo[3.2.2]nonanes, have been prepared. The new compounds were tested for their activities against one strain of the causative organism of Malaria tropica, Plasmodium falciparum K1, which is resistant against chloroquine and pyrimethamine. In addition, their cytotoxicity and their activity against the pathogen of the East African form of sleeping sickness, Trypanosoma brucei rhodesiense, were investigated. Structure-activity relationships are discussed considering data of readily prepared compounds. For the first time, a distinct in vivo activity was observed against Plasmodium berghei in a mouse model. The active compound was further investigated. Topics: Administration, Oral; Animals; Antiprotozoal Agents; Azabicyclo Compounds; Disease Models, Animal; Dose-Response Relationship, Drug; Injections, Intravenous; Male; Mice; Molecular Structure; Parasitic Sensitivity Tests; Plasmodium berghei; Plasmodium falciparum; Rats; Structure-Activity Relationship; Tissue Distribution; Trypanosoma brucei rhodesiense; Trypanosomiasis, African	2015

Article

Year

Synthesis of 3-azabicyclo[3.2.2]nonanes and their antiprotozoal activities.

Bioorganic & medicinal chemistry letters, 2015, Apr-01, Volume: 25, Issue:7

Several bicyclic compounds, 3-azabicyclo[3.2.2]nonanes, have been prepared. The new compounds were tested for their activities against one strain of the causative organism of Malaria tropica, Plasmodium falciparum K1, which is resistant against chloroquine and pyrimethamine. In addition, their cytotoxicity and their activity against the pathogen of the East African form of sleeping sickness, Trypanosoma brucei rhodesiense, were investigated. Structure-activity relationships are discussed considering data of readily prepared compounds. For the first time, a distinct in vivo activity was observed against Plasmodium berghei in a mouse model. The active compound was further investigated.

Topics: Administration, Oral; Animals; Antiprotozoal Agents; Azabicyclo Compounds; Disease Models, Animal; Dose-Response Relationship, Drug; Injections, Intravenous; Male; Mice; Molecular Structure; Parasitic Sensitivity Tests; Plasmodium berghei; Plasmodium falciparum; Rats; Structure-Activity Relationship; Tissue Distribution; Trypanosoma brucei rhodesiense; Trypanosomiasis, African

2015